🇺🇸 FDA
Patent

US 11376247

Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy

granted A61KA61K31/4025A61K31/496

Quick answer

US patent 11376247 (Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/4025, A61K31/496, A61K31/5025, A61K31/506